24P - Impact of humoral immune response against p53 on clinical outcome of High-Grade Serous Ovarian Cancer (HGSOC) patients

Date 05 November 2016
Event ESMO Symposium on Immuno-Oncology 2016
Session Lunch and general poster viewing
Presenter Marica Garziera
Citation Annals of Oncology (2016) 27 (suppl_8): viii4-viii17. 10.1093/annonc/mdw527
Authors M. Garziera1, E. Cecchin2, M. Montico2, R. Roncato2, S. Gagno2, E. De Mattia2, R. Sorio3, S. Scalone3, E. Poletto4, G. Toffoli2
  • 1Experimental And Clinical Pharmacology Unit, CRO-National Cancer Institute, 33081 - Aviano/IT
  • 2Experimental And Clinical Pharmacology Unit, CRO-National Cancer Institute, Aviano/IT
  • 3Oncology Unit C, CRO-National Cancer Institute, Aviano/IT
  • 4Oncologic Department, University of Udine, P.le S. M. della Misericordia 15, Udine/IT



The purpose of this retrospective study was to determine associations between spontaneous antibody appearance against p53 protein and clinical outcome of advanced stage ovarian cancer (OC) patients treated with a first-line platinum-based regimen after primary debulking surgery. The correlations between p53-autoantibodies (p53-AAbs) and Disease Free Survival (DFS), Overall Survival (OS) and Platinum Free Interval (PFI), were explored.


Preoperative plasma samples were collected from 64 OC patients enrolled between years 2000 and 2011 in our Institute. All patients were diagnosed with high grade (G2-G3) OC, advanced stage (III-IV), with no visible (R0) or minimal residue (R 120 U/ml were considered as positive according to the manufacturer’s instructions. Survival was compared using Kaplan-Meier, Log-rank test and Cox multivariate estimations (adjusted by surgery residue, stage, age at diagnosis).


Median age was 57 years (range 31-82). Median follow-up time was 45.7 months (range 8.2-127.7). The 28% (18/64) of OC patients were positive for p53-AAbs. Among them, 67% (12/18) had serous histotype (HGSOC). Analyses restricted to serous OC showed that presence of p53-AAbs was associated with an improved prognosis (DFS: HR 0.49 95%CI: 0.25-0.99, p = 0.047; OS: HR 0.60 95%CI: 0.27-1.31, p = 0.198; PFI: HR 0.50 95%CI: 0.25-1.02, p = 0.055). Median DFS was 20.1 and 13.1 months in patients positive and negative for p53-AAbs respectively (Log-rank p = 0.0565). Median OS was 64.1 and 44.4 months (Log-rank p = 0.3552). Median PFI was 14.1 and 7.6 months (Log-rank p = 0.0654).


These preliminary findings show that plasma p53-AAbs correlate with improved DFS in HGSOC. A trend of better outcome was also observed in OS and PFI. Our results may suggest a potential role of p53-AAbs as biomarker of adaptive immune response in HGSOC patients. Data may underlie an immunoreactive phenotype that need further investigation and confirmation in larger cohort of patients.

Clinical trial identification

Legal entity responsible for the study

CRO-National Cancer Institute


This work was supported by grant «Application of advanced nanotechnology in the development of innovative cancer diagnostic tools», AIRCx1000 Special Program Molecular Oncology (Grant number 12214)


All authors have declared no conflicts of interest.